From The Editor
This article was originally published in SRA
You've counted on Scrip Regulatory Affairs and its predecessors for many years for unrivalled coverage of global pharmaceutical and medtech regulatory affairs. Now we're making some exciting changes that will significantly enhance and expand the breadth and global reach of the content you receive.
You may also be interested in...
October and November 2020 were bad months for companies seeking to have their planned EU filings fast-tracked through the centralized drug review system at the European Medicines Agency.
Bayer has failed to convince the European Medicines Agency that its marketing authorization application for finerenone should be fast-tracked through the EU's centralized review process. There were other successes, though, although Janssen is keeping us guessing over its MAA for amivantamab. These and other developments relating to the agency's accelerated assessment mechanism are logged in this latest update to the Pink Sheet's EU accelerated assessment tracker.
A number of companies have sought to convince the European Medicine Agency that their drug merits a fast-track regulatory review.